Fu CF, Yang LF, Tian L, Deng S, Zhang Q, Yao B. Anlotinib-induced sick sinus syndrome: Two case reports. World J Clin Cases 2025; 13(6): 98084 [DOI: 10.12998/wjcc.v13.i6.98084]
Corresponding Author of This Article
Qi Zhang, Associate Chief Physician, PhD, Department of Oncology, Guizhou Provincial People’s Hospital, No. 83 Zhongshan East Road, Nanming District, Guiyang 550000, Guizhou Province, China. kekexinqing@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 26, 2025; 13(6): 98084 Published online Feb 26, 2025. doi: 10.12998/wjcc.v13.i6.98084
Anlotinib-induced sick sinus syndrome: Two case reports
Cheng-Feng Fu, Li-Fen Yang, Lei Tian, Song Deng, Qi Zhang, Biao Yao
Cheng-Feng Fu, Li-Fen Yang, Lei Tian, Song Deng, Biao Yao, Department of Oncology, Tongren People’s Hospital, Tongren 554300, Guizhou Province, China
Qi Zhang, Department of Oncology, Guizhou Provincial People’s Hospital, Guiyang 550000, Guizhou Province, China
Author contributions: Fu CF designed the report; Yang LF, Tian L, and Deng S collected the patients’ clinical data; Yao B provided key intellectual discussions; Zhang Q performed the final revision and translation of the manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qi Zhang, Associate Chief Physician, PhD, Department of Oncology, Guizhou Provincial People’s Hospital, No. 83 Zhongshan East Road, Nanming District, Guiyang 550000, Guizhou Province, China. kekexinqing@163.com
Received: June 18, 2024 Revised: October 12, 2024 Accepted: November 7, 2024 Published online: February 26, 2025 Processing time: 159 Days and 20.1 Hours
Abstract
BACKGROUND
This manuscript describes the first known cases of sick sinus syndrome (SSS) associated with the use of anlotinib in non-small cell lung cancer patients, highlighting the need for increased vigilance and cardiac monitoring.
CASE SUMMARY
Two patients with non-small cell lung cancer developed SSS after 15 months and 5 months of anlotinib treatment, respectively, presenting with syncope and palpitations. Electrocardiogram confirmed SSS, and different treatment approaches were taken for each patient. One patient received a dual-chamber permanent pacemaker, while the other discontinued the medication and experienced symptom resolution.
CONCLUSION
Anlotinib can induce SSS, suggesting that cardiac monitoring is crucial during anlotinib treatment. Individualized management strategies are necessary for affected individuals.
Core Tip: This case report presents the first known instances of sick sinus syndrome associated with the use of anlotinib in patients with non-small cell lung cancer, emphasizing the importance of cardiac monitoring during treatment. The report compares two different management approaches for anlotinib-induced sick sinus syndrome, one with a dual-chamber permanent pacemaker and the other with medication discontinuation, providing valuable insights for clinical practice.
